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Tight junctions (TJs) contribute to the paracellular barrier, 
which is a fence that divides plasma membranes and signal 
transduction, acting as a multifunctional complex in vertebrate 
epithelial and endothelial cells [1]. The morphological features 
of TJs fits well with their functions. The TJ core is a fibril-like 
proteinaceous structure within the lipid bilayer, the so-called 
TJ strands [2]. Identification and characterization of TJs-asso-
ciated proteins during the last two decades has unveiled the 
nature of TJ strands and how they are spatially organized. The 
interplay between integral membrane proteins, claudins, and 
cytoplasmic plaque proteins, ZO-1/ZO-2, is critical for TJ for-
mation and function [3]. 
Among the TJ-associated proteins, the claudin family of 
membrane proteins, identified in 1998 by the Tsukita group, 
are key molecules in the architecture and barrier function of 
TJs [4]. Claudins maintain cell polarity and are involved in re-
cruiting signaling proteins. Claudins are also hypothesized to 
be involved in the regulation of proliferation, differentiation, 
and other cellular functions [5].
TJ dysfunction has been presumed as a mechanism for the 
loss of cell adhesion and an important step in the progression 
of cancer to metastasis. Because claudin expression patterns 
are tissue- and cell-specific, recent studies have suggested that 
claudins might be useful molecular markers for many differ-
ent cancers [6,7]. Moreover, claudins are a potential target for 
novel antibody-based therapies of diverse cancers [8].
Until now, 24 members of the claudin family have been iden-
tified. The role of claudins in breast cancer is unknown and not 
well-explored, but recent reports have shown that claudins 3 
and 4 are overexpressed in breast cancer, whereas claudins 1 
and 7 are downregulated or completely absent [9-11]. Further-
more, Szasz et al. [12] indicated that the loss of claudins might 
contribute to breast cancer progression, and that certain clau-
din expression patterns might be of prognostic relevance. These 
results suggest that claudin subtypes may have different roles 
during different stages of breast cancer.
Claudin-6 is expressed during the early stage of epidermal 
morphogenesis and is crucial to epidermal differentiation and 
barrier formation [13]. A recent report showed that claudin-6 is 
preferentially expressed in mammary epithelial cells and func-
tions as a breast cancer tumor suppressor [14]. Additionally, 
Osanai et al. [15] suggested that the claudin-6 methylator phe-
notype might contribute to enhance tumorigenic and invasive 
properties of breast cancer cells. However, no information is 
available on the regulating mechanism of claudin-6 expression 
in breast cancer. In this study by Yafang et al. [16], authors dem-
onstrated that estrogen induces claudin-6 expression through 
an estrogen receptor (ER) α pathway in MCF-7 cells. The data 
are clear, and this is the first report showing that claudin-6 ex-
pression was associated with ERα in breast cancer cells. How-
ever, first of all, authors had to indicate how claudin-6 expres-
sion is related to ERs. It was necessary to study claudin-6 ex-
pression in ER (+) and ER (-) breast cancer (prior to ERα and 
ERβ cells). Authors described in their previous studies that no 
significant association was found between claudin-6 expression 
and ER (+) breast cancer (even ERs). It is well accepted that 
the MCF-7 cell line may vary depending on in vitro culture 
conditions. Therefore, disparate results may occur during in 
vitro selection conditions. Although results from a laboratory 
setting may not exactly correlate with in vivo results, there is lit-
tle significance to a research finding that only has significance 
in vitro. Because claudin-6 expression was also observed in 
ERβ (+) breast cancer cells, authors must show that claudin-6 
is expressed in the MDA-MB-231 cancer cell line and demon-
strate that the ERβ pathway is not associated with this protein 
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expression. But this was also omitted. Thus, further investiga-
tion with a much larger cohort should be performed to con-
firm the relationship between claudin-6 and ERs. 
Claudin expression is associated with breast cancer prognosis. 
Down-regulation of claudin-2 is significantly associated with 
lymph node metastasis and high clinical stage [17]. Addition-
ally, high levels of claudin-4 are associated with adverse out-
comes in patients with breast cancer [18]. Therefore, it is also 
necessary to evaluate the clinicopathological parameters of 
breast cancers to determine whether claudin-6 could be used 
as a predictor of survival or prognosis.
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